Intercept ICPT reported positive top-line results from its phase 3 results of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH) on Feb. 19. The trial ...

In a crowded field of nonalcoholic steatohepatitis (NASH) hopefuls, Intercept Pharmaceuticals looks to be pulling ahead. In a pivotal phase 3 study, the biotech’s obeticholic acid (OCA) met its ...

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Trial met the primary efficacy ...

NEW YORK, May 20, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel ...

Intercept Pharmaceuticals, Inc. ICPT announced initial results from a planned interim analysis of its ongoing phase II study 747-213. The comparative study is evaluating the therapeutic potential of ...

A drug in development for nonalcoholic steatohepatitis took a step closer to regulatory approval Tuesday with the announcement of positive results from a Phase III clinical trial, which analysts said ...

NEW YORK, April 13 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced the presentation of the results from its recently completed Phase II clinical trial of INT-747 (obeticholic acid) in ...

Intercept Pharmaceuticals, Inc. ICPT announced positive additional supportive data from its pivotal phase III REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to ...